BBI-2000
/ Fresh Tracks Therap, The University of Manchester
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 17, 2017
Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis
(clinicaltrials.gov)
- P1; N=47; Completed; Sponsor: Brickell Biotech, Inc.; Active, not recruiting ➔ Completed
Trial completion • Biosimilar • Dermatitis • Immunology • Inflammation
1 to 1
Of
1
Go to page
1